Abstract 4518: Proteolysis targeting chimera (PROTAC)-driven internalization of antibodies targeting oncogenic cell surface receptors
Ezequiel J. Tolosa(Mayo Clinic), Aaron S. Mansfield(Mayo Clinic), Jennifer Ayers-Ringler(Mayo Clinic), Amar Natarajan(Nebraska Medical Center), Farhad Kosari(Mayo Clinic), Janet Schaefer-Klein(Mayo Clinic), Lin Yang(Mayo Clinic), Jayapal Reddy Mallareddy(University of Nebraska Medical Center)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
|Journal of Oncology Practice|2017|447